Treatment to prevent recurrent genital herpes
暂无分享,去创建一个
[1] A. Wald,et al. Famciclovir Reduces Viral Mucosal Shedding in HSV-Seropositive Persons , 2007, Sexually transmitted diseases.
[2] A. Dupuy,et al. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. , 2007, Journal of the American Academy of Dermatology.
[3] A. Wald,et al. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. , 2007, The Journal of infectious diseases.
[4] J. Dummer,et al. Herpes Simplex and Varicella Zoster Viruses: Forgotten but Not Gone , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[5] Vincent Foulongne,et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. , 2007, The New England journal of medicine.
[6] T. Warren,et al. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial. , 2006, Mayo Clinic proceedings.
[7] F. Aoki,et al. Comparative Efficacy of Famciclovir and Valacyclovir for Suppression of Recurrent Genital Herpes and Viral Shedding , 2006, Sexually transmitted diseases.
[8] K. Workowski,et al. Sexually transmitted diseases treatment guidelines, 2006. , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[9] A. Wald,et al. Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] J. Molina,et al. Topical imiquimod for recurrent acyclovir-resistant HSV infection. , 2006, The American journal of medicine.
[11] G. Hornor. Ano-genital herpes in children. , 2006, Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners.
[12] M. Steben. Genital Herpes Simplex Virus Infection , 2005, Clinical obstetrics and gynecology.
[13] A. Caughey,et al. Acyclovir prophylaxis for pregnant women with a known history of herpes simplex virus: a cost-effectiveness analysis. , 2005, American journal of obstetrics and gynecology.
[14] D. Fisman. Health related quality of life in genital herpes: a pilot comparison of measures , 2005, Sexually Transmitted Infections.
[15] B. Herold,et al. Topical microbicides for the prevention of genital herpes infection. , 2005, The Journal of antimicrobial chemotherapy.
[16] J. Baeten,et al. Contribution of HIV-1 infection to acquisition of sexually transmitted disease: a 10-year prospective study. , 2005, The Journal of infectious diseases.
[17] M. Levin,et al. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] J. Druce,et al. Changing epidemiology of genital herpes simplex virus infection in Melbourne, Australia, between 1980 and 2003 , 2004, Sexually Transmitted Infections.
[19] D. Rouse,et al. Clinical practice. Genital herpes. , 2004, The New England journal of medicine.
[20] S. Sacks. Famciclovir suppression of asymptomatic and symptomatic recurrent anogenital herpes simplex virus shedding in women: a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-center trial. , 2004, The Journal of infectious diseases.
[21] T. Quinn,et al. The Effects of Herpes Simplex Virus-2 on HIV-1 Acquisition and Transmission: A Review of Two Overlapping Epidemics , 2004, Journal of acquired immune deficiency syndromes.
[22] J. Malkin. Epidemiology of genital herpes simplex virus infection in developed countries. , 2004, Herpes : the journal of the IHMF.
[23] A. Wald,et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. , 2004, The New England journal of medicine.
[24] E. Andrews,et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984-1999. , 2004, Birth defects research. Part A, Clinical and molecular teratology.
[25] H. Weiss,et al. Epidemiology of herpes simplex virus type 2 infection in the developing world. , 2004, Herpes : the journal of the IHMF.
[26] D. Raoult,et al. Surveillance Network for Herpes Simplex Virus Resistance to Antiviral Drugs: 3-Year Follow-Up , 2004, Journal of Clinical Microbiology.
[27] James B. Hill,et al. Acyclovir Prophylaxis to Prevent Herpes Simplex Virus Recurrence at Delivery: A Systematic Review , 2003, Obstetrics and gynecology.
[28] Edwin DeJesus,et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. , 2003, The Journal of infectious diseases.
[29] G. Kleymann. New antiviral drugs that target herpesvirus helicase primase enzymes. , 2003, Herpes : the journal of the IHMF.
[30] G. Burstein,et al. Sexually transmitted diseases treatment guidelines , 2003, Current opinion in pediatrics.
[31] L. Corey,et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. , 2003, American journal of obstetrics and gynecology.
[32] L. Corey,et al. Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research , 2003, Clinical Microbiology Reviews.
[33] W. Snowden,et al. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. , 2002, The Journal of infectious diseases.
[34] Zengri J. Wang,et al. Imiquimod 5-Percent Cream Does Not Alter the Natural History of Recurrent Herpes Genitalis: a Phase II, Randomized, Double-Blind, Placebo-Controlled Study , 2002, Antimicrobial Agents and Chemotherapy.
[35] W. Reeves,et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. , 2003, Archives of internal medicine.
[36] R. Boon,et al. Surveillance for Antiviral-Agent-Resistant Herpes Simplex Virus in the General Population with Recurrent Herpes Labialis , 2002, Antimicrobial Agents and Chemotherapy.
[37] G. Hoekzema,et al. Neonatal herpes simplex virus infections. , 2002, American family physician.
[38] T. Schacker,et al. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials , 2002, International journal of STD & AIDS.
[39] J. Weinberg,et al. Topical imiquimod for acyclovir-unresponsive herpes simplex virus 2 infection. , 2001, Archives of dermatology.
[40] B. Goldman. Herpes serology for dermatologists. , 2000, Archives of dermatology.
[41] P. Crosson,et al. Antiviral susceptibilities of herpes simplex virus from immunocompetent subjects with recurrent herpes labialie: a UK-based survey. , 2000, The Journal of antimicrobial chemotherapy.
[42] F. Aoki,et al. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals , 2000 .
[43] S. Tyring,et al. Relation between herpes simplex viruses and human immunodeficiency virus infections. , 1999, Archives of dermatology.
[44] W. Hardy,et al. Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study. , 1999, Journal of acquired immune deficiency syndromes.
[45] L. Corey,et al. Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease. , 1999, Sexually transmitted diseases.
[46] A. Wald,et al. Genital Herpes: Review of the Epidemic and Potential Use of Type-Specific Serology , 1999, Clinical Microbiology Reviews.
[47] J. Zeh,et al. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. , 1998, The Journal of infectious diseases.
[48] S. Trottier,et al. A Multicenter Phase I/II Dose Escalation Study of Single-Dose Cidofovir Gel for Treatment of Recurrent Genital Herpes , 1998, Antimicrobial Agents and Chemotherapy.
[49] S. Shafran,et al. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. , 1998, JAMA.
[50] L. Corey,et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. , 1998, The Journal of infectious diseases.
[51] G. Darby,et al. Survey of Resistance of Herpes Simplex Virus to Acyclovir in Northwest England , 1998, Antimicrobial Agents and Chemotherapy.
[52] P. Brocklehurst,et al. A randomised placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection , 1998, British journal of obstetrics and gynaecology.
[53] S. Lee,et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. , 1997, The Journal of infectious diseases.
[54] N. Bodsworth,et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group. , 1997, Genitourinary medicine.
[55] M. Loveless,et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. , 1997, Archives of internal medicine.
[56] M. Loveless,et al. Oral Famciclovir for Suppression of Recurrent Genital Herpes Simplex Virus Infection in Women: A Multicenter, Double-Blind, Placebo-Controlled Trial , 1997 .
[57] D. Kuritzkes,et al. Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172). AIDS Clinical Trials Group. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[58] J. Feldman,et al. Increased Genital Shedding of Herpes Simplex Virus Type 2 in HIV-Seropositive Women , 1995, Annals of Internal Medicine.
[59] L. Corey,et al. Recurrence Rates in Genital Herpes after Symptomatic First-Episode Infection , 1994, Annals of Internal Medicine.
[60] A. Wagstaff,et al. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. , 1994, Drugs.
[61] A. Morley,et al. Topical trifluridine for mucocutaneous acyclovir-resistant herpes simplex II in AIDS patient , 1992, The Lancet.
[62] M. Carrier,et al. Prevention of herpes simplex virus infection by oral acyclovir after cardiac transplantation. , 1992, Canadian journal of surgery. Journal canadien de chirurgie.
[63] J. Foidart,et al. Acyclovir vs isoprinosine (immunovir) for suppression of recurrent genital herpes simplex infection. , 1992, Genitourinary medicine.
[64] C. Crumpacker,et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. , 1991, The New England journal of medicine.
[65] P. Catalano,et al. Incidence of genital herpes simplex virus at the time of delivery in women with known risk factors. , 1991, American Journal of Obstetrics and Gynecology.
[66] C. Crumpacker,et al. Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection , 1991, JAMA.
[67] R. Kaufman,et al. One-Year Suppression of Frequent Recurrences of Genital Herpes With Oral Acyclovir , 1989, Obstetrics and gynecology.
[68] H. Erlich,et al. A new look at the shared epitope hypothesis. , 1988, The American journal of medicine.
[69] S. Mostow,et al. Suppression of recurrent genital herpes by single daily dosages of acyclovir. , 1988, The American journal of medicine.
[70] R. Greenblatt,et al. Genital ulceration as a risk factor for human immunodeficiency virus infection. , 1988, AIDS.
[71] H. Stiver,et al. Chronic Suppression for Six Months Compared With Intermittent Lesional Therapy of Recurrent Genital Herpes Using Oral Acyclovir: Effects on Lesions and Nonlesional Prodromes , 1988, Sexually transmitted diseases.
[72] G. Jackson,et al. Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. , 1985, JAMA.
[73] T. Hovi,et al. PROPHYLACTIC ORAL ACYCLOVIR AFTER RENAL TRANSPLANTATION , 1985, Transplantation.
[74] R. Reichman. Herpes simplex virus infections , 1984, European Journal of Clinical Microbiology.
[75] D. Hindley,et al. PROPHYLACTIC ORAL ACYCLOVIR IN RECURRENT GENITAL HERPES , 1984, The Lancet.
[76] L. Corey,et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. , 1984, The New England journal of medicine.
[77] D. Alling,et al. Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. , 1984 .
[78] N. Flournoy,et al. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. , 1984, Annals of internal medicine.
[79] E. Gluckman,et al. PROPHYLAXIS OF HERPES INFECTIONS AFTER BONE-MARROW TRANSPLANTATION BY ORAL ACYCLOVIR , 1983, The Lancet.
[80] O. Laskin,et al. Acyclovir prophylaxis of herpes-simplex-virus infections. , 1981, The New England journal of medicine.
[81] M. Piazza,et al. HEPATITIS B NOT TRANSMISSIBLE VIA FÆCAL-ORAL ROUTE , 1975, The Lancet.
[82] R. Sarisky,et al. Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials , 2003, Archives of Virology.
[83] A. Wald,et al. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. , 2002, The Journal of infectious diseases.
[84] P. Sánchez,et al. Acyclovir suppression to prevent recurrent genital herpes at delivery. , 2002, Infectious diseases in obstetrics and gynecology.
[85] F. Aoki,et al. Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group. , 2000, AIDS.
[86] Boon,et al. Antiviral susceptibilities of herpes simplex virus from immunocompetent subjects with recurrent herpes labialis: a UK-based survey. , 2000, The Journal of antimicrobial chemotherapy.
[87] J. Zeh,et al. Famciclovir for the Suppression of Symptomatic and Asymptomatic Herpes Simplex Virus Reactivation in HIV-Infected Persons: A Double-Blind, Placebo-Controlled Trial , 1998, Annals of Internal Medicine.
[88] D. Faulds,et al. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. , 1994, Drugs.
[89] L. Corey,et al. Double-blind, placebo-controlled trial comparing long-term suppressive with short-term oral acyclovir therapy for management of recurrent genital herpes. , 1988, The American journal of medicine.